Breye Therapeutics has a paper on its oral danegaptide treatment for patients with NPDR published in Science Translational Medicine

Likely Human

www.globenewswire.comby Breye TherapeuticsSeptember 23, 2026Submitted September 23, 2026

Oral treatment danegaptide represents “a potential paradigm shift” toward earlier, non-invasive treatment of Non-Proliferative Diabetic Retinopathy (NPDR), say authorsStudy “provides compelling evidence” that...

The Verdict

ClassificationLikely Human

ConfidenceMedium confidence

Analyzedtext

Community Verdict

Be the first to vote on this assessment.

Embed Badge

Add this badge to your site to show the AI classification for this content.

[![Real Press](https://real.press/api/badge/f9268194-c709-43aa-b839-66fd1b45588c)](https://real.press/content/f9268194-c709-43aa-b839-66fd1b45588c)